

PCT
JC02 Rec'd PCT/PTO 15 MAY 2002

INFORMATION DISCLOSURE
STATEMENT

Patent Application
Docket No. GJE-82
Serial No. 10/069,099

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231 on May 6, 2002



David R. Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christopher Robin Lowe, Kim Hilary Lawden
Serial No. : 10/069,099
Filed : November 9, 2001
For : Novel Triazine-Based Detoxification Agents and Their Use

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
AUG 01 2002
TC 1700

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. The Applicants have been notified that a copy of the international search report and copies of the references cited therein have been made available in the national stage file as indicated on the Notification of Missing Requirements Under 35 USC §371 (Form PTO/DO/EO/905). Therefore, copies of the documents cited in the international search report are not enclosed as these documents are already available in the national stage file. However, a form PTO-1449 listing the references is attached. In accordance with 37 CFR §1.56, the Applicants hereby request that the references cited in the international search report and listed on the attached form PTO-1449 be made of record and considered in the examination of the subject application.

The Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address : 2421 N.W. 41st Street, Suite A-1
Gainesville, Florida 32606-6669

DRS/la

Attachment: Form PTO-1449



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/069,099
Filing Date	November 9, 2001
First Named Inventor	Christopher Robin Lowe
Art Unit	
Examiner Name	
Attorney Docket Number	GJE-82

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-4,229,537	10/21/1980	Hodgins <i>et al.</i>	
	U2	US-4,491,660	01/01/1985	Gendrich <i>et al.</i>	
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

RECEIVED
AUG 01 2002
TC 1700

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	2 092 470 A	08/18/1982	Tanabe Seiyaku		
	F2	0 350 004 A2	01/10/1990	Tanabe Seiyaku		
	F3	0 431 593 A2	06/12/1991	Daicel Chemical		
	F4	WO 96/41185	12/19/1996	Perseptive Biosystems		
	F5	WO 97/10887	03/27/1997	Novo Nordisk		
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/069,099
Filing Date	November 9, 2001
First Named Inventor	Christopher Robin Lowe
Group Art Unit	
Examiner Name	
Attorney Docket Number	GJE-82

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BURTON, NICOLAS P. and CHRISTOPHER R. LOWE "Design of Novel Affinity Adsorbents for the Purification of Trypsin-Like Proteases" <i>Journal of Molecular recognition</i> 5:55-68, 1992.	
	R2		
	R3		
	R4		
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

RECEIVED
AUG 01 2002
TC 1700

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.